<div id="readability-page-1"><p>Shares of Markel Group Inc. (NYSE:MKL - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $2,199.90 and last traded at $2,190.9950, with a volume of 3321 shares traded. The stock had previously closed at $2,182.67.</p><h2>Key Headlines Impacting Markel Group</h2><ul><li>Update! What Is Congress Trading So Far In 2025? </li></ul><p>Here are the key news stories impacting Markel Group this week:</p><ul>   <li><span>Positive Sentiment: </span>Zacks raised several near‑term quarter estimates and FY2026: Q1 2026 to $25.38 (from $25.18), Q2 2026 to $28.56 (from $28.03), Q3 2026 to $27.34 (from $27.20) and FY2026 to $111.15 (from $109.94). These upgrades suggest Zacks sees stronger earnings momentum into FY2026, supporting upside for MKL. <i></i><span>MarketBeat MKL</span></li>    <li><span>Positive Sentiment: </span>Zacks also increased near‑term 2027 quarter forecasts: Q1 2027 to $32.59 (from $32.25) and Q2 2027 to $29.10 (from $28.79). Upward tweaks for early 2027 quarters can lift sentiment ahead of future earnings releases. <i></i><span>MarketBeat MKL</span></li>    <li><span>Neutral Sentiment: </span>Zacks continues to rate MKL &#34;Strong‑Buy&#34; and included the stock in a Zacks momentum piece highlighting buy candidates, which can attract attention from momentum‑focused funds but is not a direct earnings driver. <i></i><span>Best Momentum Stocks to Buy for Dec. 22</span></li>    <li><span>Negative Sentiment: </span>One modest cut: Zacks trimmed its Q3 2027 EPS estimate to $25.81 from $26.07. It's a small downward tweak that could temper some near‑term expectations but appears outweighed by the other upgrades. <i></i><span>MarketBeat MKL</span></li> </ul><h2>Analyst Upgrades and Downgrades</h2><p>Several analysts have recently weighed in on the company. Cowen  restated a &#34;hold&#34; rating on shares of Markel Group in a report on Tuesday, October 7th. Weiss Ratings  reiterated a &#34;buy (b+)&#34; rating on shares of Markel Group in a report on Monday, December 15th. Finally, Zacks Research upgraded Markel Group from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Friday. One investment analyst  has rated the stock with a Strong Buy rating, two have assigned  a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $2,025.00.</p><ul><li>Buffett's latest portfolio additions, trims and cuts in Q3</li></ul><p><b>View Our Latest Research Report on Markel Group</b></p><h2>Markel Group Trading Up 0.6%</h2><p>The firm's 50 day simple moving average is $2,024.91 and its two-hundred day simple moving average is $1,981.75. The company has a quick ratio of 0.60, a current ratio of 0.60 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $27.70 billion, a P/E ratio of 13.75 and a beta of 0.81. </p><ul><li>Don't Overlook Hidden Gem Kinsale As Rallies To New Highs</li></ul><p>Markel Group (NYSE:MKL - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The insurance provider reported $30.90 EPS for the quarter, beating analysts' consensus estimates of $22.77 by $8.13. Markel Group had a return on equity of 7.76% and a net margin of 12.99%.The firm had revenue of $3.93 billion during the quarter, compared to analysts' expectations of $3.77 billion.  As a group, analysts forecast that  Markel Group Inc. will post 96.25 earnings per share for the current fiscal year. </p><h2>Insider Activity at Markel Group</h2><p>In related news, CEO Simon Wilson sold 75 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $2,072.94, for a total value of $155,470.50. Following the completion of the sale, the chief executive officer directly owned 1,770 shares of the company's stock, valued at approximately $3,669,103.80. This represents a 4.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Steven A. Markel sold 1,330 shares of the firm's stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $2,119.12, for a total value of $2,818,429.60. Following the transaction, the director owned 60,368 shares in the company, valued at approximately $127,927,036.16. This trade represents a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 1,575 shares of company stock valued at $3,330,900. Company insiders own  1.66% of the company's stock. </p><h2>Hedge Funds Weigh In On Markel Group</h2><p>Several institutional investors have recently added to or reduced their stakes in the stock. Canerector Inc. boosted its stake in  Markel Group by 191,036.0% in the third quarter. Canerector Inc. now owns 10,703,616 shares of the insurance provider's stock valued at $20,458,463,000 after acquiring an additional 10,698,016 shares during the last quarter.  Select Equity Group L.P. purchased a new position in  Markel Group in the first quarter valued at approximately $357,512,000.  Norges Bank purchased a new position in  Markel Group in the second quarter valued at approximately $288,361,000.  Epoch Investment Partners Inc. increased its position in  Markel Group by 49.5% in the first quarter. Epoch Investment Partners Inc. now owns 108,019 shares of the insurance provider's stock worth $201,953,000 after buying an additional 35,786 shares during the last quarter.  Finally, Rakuten Investment Management Inc. purchased a new stake in  Markel Group in the third quarter worth $46,738,000. Institutional investors own  77.12% of the company's stock. </p><h2>About Markel Group</h2> (Get Free Report)<p>Markel Group <span>NYSE: MKL<span></span></span> is a diversified insurance holding company best known for underwriting specialty insurance products. Founded in 1930 and headquartered in Richmond, Virginia, the company provides a wide range of commercial property and casualty coverages tailored to niche and hard-to-place risks. Its underwriting operations focus on specialty lines across multiple industries, delivering customized policy structures, program administration, and claims management services for complex exposures.  </p><p>In addition to primary specialty insurance, Markel operates reinsurance and alternative risk-transfer activities and manages invested assets derived from underwriting float.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Markel Group</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Markel Group Right Now?</h2><p>Before you consider Markel Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Markel Group wasn't on the list.</p><p>While Markel Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Markel Group (NYSE:MKL) reached a new 52-week high, trading as high as $2,199.90. Zacks upgraded its earnings estimates for FY2026 and early 2027, maintaining a 'Strong-Buy' rating. Analysts have mixed ratings, with an average 'Moderate Buy' and a target price of $2,025.00. Recent insider sales included CEO Simon Wilson and Director Steven A. Markel. Institutional investors like Canerector Inc. significantly increased their stakes.</p>

Markel Group (NYSE:MKL) Reaches New 52-Week High - Here's What Happened